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Abstract
Background: Sulfadoxine-pyrimethamine was a common first line drug therapy to treat uncomplicated falciparum malaria,
but increasing therapeutic failures associated with the development of significant levels of resistance worldwide has
prompted change to alternative treatment regimes in many national malaria control programs.
Methodology and Finding: We conducted an in vivo therapeutic efficacy trial of sulfadoxine-pyrimethamine at two
locations in the Peruvian Amazon enrolling 99 patients of which, 86 patients completed the protocol specified 28 day follow
up. Our objective was to correlate the presence of polymorphisms in P. falciparum dihydrofolate reductase and
dihydropteroate synthase to in vitro parasite susceptibility to sulfadoxine and pyrimethamine and to in vivo treatment
outcomes. Inhibitory concentration 50 values of isolates increased with numbers of mutations (single [108N], sextuplet [BR/
51I/108N/164L and 437G/581G]) and septuplet (BR/51I/108N/164L and 437G/540E/581G) with geometric means of 76 nM
(35–166 nM), 582 nM (49-6890- nM) and 4909 (3575–6741 nM) nM for sulfadoxine and 33 nM (22–51 nM), 81 nM (19–
345 nM), and 215 nM (176–262 nM) for pyrimethamine. A single mutation present in the isolate obtained at the time of
enrollment from either dihydrofolate reductase (164L) or dihydropteroate synthase (540E) predicted treatment failure as well
as any other single gene alone or in combination. Patients with the dihydrofolate reductase 164L mutation were 3.6 times as
likely to be treatment failures [failures 85.4% (164L) vs 23.7% (I164); relative risk=3.61; 95% CI: 2.14 – 6.64] while patients
with the dihydropteroate synthase 540E were 2.6 times as likely to fail treatment (96.7% (540E) vs 37.5% (K540); relative
risk=2.58; 95% CI: 1.88 – 3.73). Patients with both dihydrofolate reductase 164L and dihydropteroate synthase 540E mutations
were 4.1 times as likely to be treatment failures [96.7% vs 23.7%; RR=4.08; 95% CI: 2.45 – 7.46] compared to patients having
both wild forms (I164 and K540).
Conclusions: In this part of the Amazon basin, it may be possible to predict treatment failure with sulfadoxine-
pyrimethamine equally well by determination of either of the single mutations dihydrofolate reductase 164L or
dihydropteroate synthase 540E.
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Introduction
As the therapeutic efficacy of chloroquine for treatment of
uncomplicated P. falciparum malaria declined in the late 1980s and
early 1990s worldwide, sulfadoxine-pyrimethamine (SP; trade
name Fansidar) was introduced as a replacement first line
treatment. SP is an inexpensive fixed dose combination tablet
which is well tolerated, highly efficacious, and can be administered
in a single dose thus insuring compliance, making this drug ideal
for first line therapy for uncomplicated malaria. However, drug
resistance can occur rapidly [1,2,3] prompting ministries of health
to change treatment policies [4]. SP was introduced as second line
therapy in 1993 and first-line therapy in 1997 in the Amazon basin
of Peru to counter widespread chloroquine resistance [5].
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6762The mode of action of SP is well understood [6]. It is known
that pyrimethamine and sulfadoxine preferentially bind to and
inhibit the malaria parasite’s dihydrofolate reductase (DHFR) and
dihydropteroate synthase (DHPS) enzymes respectively, prevent-
ing de novo folic acid synthesis [7,8]. The process of development of
drug resistance against pyrimethamine occurs in a stepwise fashion
commencing with the codon108N mutation in Pfdhfr followed by
subsequent mutations at 50R, 51I, 59R and 164L [1]. A similar
process occurs in Pfdhps, leading to resistance to sulfadoxine.
Selection of antimalarial therapies that affect similar pathways
within the host cell and malaria parasite is cause for concern but in
the case of SDX and PYR, they appear to have little toxic effects
on host cell survivability [9]. In vivo drug resistance in Peru was
shown previously to be highly correlated with the presence of the
DHFR haplotype 108N/51I/164L and DHPS haplotype 437G/
540E/581G [10]. Insertion of the additional amino acids GKKNE
at codon 30 of DHFR, termed the Bolivia repeat, has only been
found in isolates from South America but a clear association of this
repeat and drug sensitivity has not been shown [5,11]. A single
DHFR mutation at 59R along with a single DHPS mutation at
540E in certain parasite populations have been used to predict the
presence of the quintuplet mutant and subsequent in vivo resistance
[10] while in other population 437G is predictive [12,13].
Interestingly, the polymorphism at 164L is uncommon in Africa
[14,15] which is contrary to South America were it is found at a
high frequency in patients that fail SP treatment [5].
There are few published reports correlating patient outcomes
following treatment with SP and in vitro drug susceptibility values
obtained from ex vivo parasites [16]. This could be due to the
difficulties associated with antimalarial therapies effecting de novo
folate synthesis since most cell culture medias contain folic acid and
would necessitate the use of folate free media, which is costly [17].
Favorable treatment outcomes to antimalarials, including SP,
are dependent on host immune responses and pharmacodynamics
[18,19,20]. The combination of inadequate dosing and lack of
acquired immunity among children especially, can give high
treatment failure [21]. Therefore studies that evaluate in vivo and in
vitro drug susceptibility of the same parasite isolates are needed to
demonstrate key parasite specific factors that contribute to
observed outcomes.
The purpose of the present study was to evaluate the therapeutic
efficacy of SP in two locations in the Amazon rainforest region of
Peru, and to correlate the presence of molecular markers
associated with drug resistance and the Bolivia repeat sequence
with in vitro drug susceptibility levels of sulphadoxine and
pyrimethamine and treatment outcome. In vivo outcomes for
one of these trials have been previously reported [22].
Results
Mutational analysis
We successfully genotyped all isolates collected during the
enrollment process. The results of the genotyping produced three
different two-locus haplotype for the DHFR/DHPS loci: single
mutant (108N), sextuplet (BR/51I/108N/164L and 437G, 581G)
or septuplet (BR/51I/108N/164L and 437G/540E/581G) with
an overall frequency of 44%, 21% and 35%, respectively. No
other two-locus haplotypes were identified. Genotypes of PfDHFR
and PfDHPS and how they relate to clinical outcomes are
summarized in Table 1. The presence of the sextuplet and
septuplet were highly correlated with clinical failure (p,0.01). The
Polymorphisms that were always present (108N) or always absent
(A16, C50, C59, S436, and A613) provided no information on risk
to treatment failure in this study (data not shown). Table 2
provides the treatment failure rates (and relative risk) depending
on the number of mutations in DHFR, DHPS, and DHPF/
DHFR. In all cases there is increasing risk of failure with numbers
of mutations. The presence of 164L of DHFR and 540E of DHPS
contained in the septuplet were an excellent predictor of treatment
failures, with 96.7% of the patients having an isolates harboring
this combination, failing treatment.
In vivo efficacy outcomes
Of 159 patients assessed for eligibility, 99 were enrolled in the
study (Figure 1) and 86 patients completed the study, of which, 52
were enrolled during the months of March through May 1999 in
Table 1. Occurrence of mutations
1 and treatment outcome [25].
Person No. WHO 2003
1 DHFR codon
2 DHPS codon No. of mutations (Total)
4
N 108N 51I 164L BR
3 581G 437G 540E
1–29 29 ACPR + 1
30–35 6 ACPR + +++++ 6
36 1 ACPR + 7
37–44 8 LPF ++ 1
45–54 10 LPF ++ ++ ++ ++ ++ ++ 6
55–67 13 LPF ++ ++ ++ ++ ++ ++ ++ 7
68 1 LCF ++ ++ ++ ++ ++ ++ ++ 7
69 1 ETF ++ 1
70–71 2 ETF ++ ++ ++ ++ ++ ++ 6
72–86 15 ETF ++ ++ ++ ++ ++ ++ ++ 7
86
1WHO 2003 definitions: ACPR, LPF, LCF, ETF.
2Blank cells indicate wild –type sequence at the indicated codon; + indicate a mutation at the codon present in malaria isolates that were sensitive to SP; ++ indicate
mutation present in malaria isolates that were resistant to SP.
3Bolivian Repeat insert.
4Genotypes: (1) DHFR 108/51/64 (with BR); (2) DHPS 581/437/540;
doi:10.1371/journal.pone.0006762.t001
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to August 1999 [22]. The original IRB approved protocol stated
that clinical outcomes would be determined using the 1973 WHO
system for classification [23] which focuses on parasitologic
outcomes. During later analysis, the 2003 WHO system for
categorizing outcomes, which includes a clinical component to the
outcome category, was also assessed. Overall, the 2003 and 1973
WHO classification systems were in agreement, regardless of study
site location (data not shown), in 99% (85/86) of the treatment
outcomes [24]. Of the 36 persons who were treatment cures by at
least one WHO criterion, 97% (35/36) were in agreement. There
was no difference in the treatment cure rates (S% or ACPR %):
41% (35/86; 95% CI: 30.2%–51.8%) were successfully cured
following treatment with SP using the 1973 method while 42%
(36/86; 95% CI: 31.3%–52.9%) were cured when classified using
the 2003 system [24]. There was also no difference in the times-to-
treatment failure for the two WHO systems (data not shown).
Because the two WHO classification systems gave comparable
results, only the WHO 2003 classification results will be reported
for subsequent analysis. Gametocyte densities were determined for
all enrolled patients up to the time when they failed treatment.
Patients that failed treatment with SP were no longer followed as
part of this study, including weekly bleedings to determine
gametocyte carriage rates. Therefore, 21 of the 22 patients from
Padre Cocha classified as having ACPR and parasite clearance
times (PCT) of 2–3 days following treatment, had gametocyte
carriage densities determined by trained laboratory personnel on
days 3, 7, 14 and 28. Nineteen of the 21 patients harbored a
parasite with a single mutation in DHFR (108N) while two of 21
harbored parasites with the sextuplet haplotype (BR/51I/108N/
164L and 437G/581G). In order to characterize transmission
potential, the area under the curve (AUC) for the entire group
classified as having ACPR (n=21) was determined and calculated
to be 3.8 [25]. Additionally, an average AUC for three separate
groups, based on PCT, were determined. An AUC of 1.6 was
calculated from one patient with a PCT=1 day and 3.5 and 3.6
from patients with a PCT=2 days (n=10) and 3 days (n=9),
respectively. Eleven of the 19 patients (58%) harboring parasites
containing the single mutation (108N) had gametocytes at day 28
(17–252 gametocytes/ml) while seven of the remaining eight had
gametocyte present on day 21. One of the two parasites with the
sextuplet haplotype had a 2-fold higher gametocyte density at day
14 compared to the rest of the group but this fell to 62
gametocytes/ml by day 28 while the remaining patient with the
parasite harboring the sextuplet cleared gametocytes by day 7.
Isolates collected on the day of failure from all patients that
failed treatment had 100% identical RFLP patterns for Pfmsp2,
and DNA sequence identify for Pfmsp1 block 2, when compared to
isolates collected on day of enrollment, providing evidence that
treatment failure was due to recrudescence not reinfection. At least
nine genotypes of Pfmsp2 as determined by PCR RFLP and seven
genotypes of Pfmsp1 block 2 as determined by DNA sequencing
have been shown previously to be circulating in this region of Peru
[26,27]. We did not observe mixed infections from the DNA
sequences, which has since been confirmed using a heteroduplex
tracking assay [28]; Juliano and Meshnick, unpublished).
In addition, age, gender, weight, number of episodes of malaria
in last year, species of previous malaria case and subsequent
treatment of previous malaria case were not associated with
treatment outcomes (data not shown). Additionally, serum was
Table 2. Risk of treatment failure associated with occurrences of mutant alleles from DHPS, DHFR, and in combination.
Treatment Outcome
1




No. of mutants F S
108N 9 29 38 23.7 1
BR/51I/108N/164L 41 7 48 85.4 3.61 2.14–6.64
Total 50 36 86 58.1 - -
Treatment Outcome
1




No. of mutants F S
0 9 29 38 23.7 1 -
437G/581G 12 6 18 66.7 2.82 1.47–5.46
437G/540E/581G 29 1 30 96.7 4.08 2.45–7.46







No. mutants F S Total
1 9 29 38 23.7 1 -
BR/51I/108N/164L and 437G/581G 12 6 18 66.7 2.82 1.47–5.46
BR/51I/108N/164L and 437G/540E/581G 29 1 30 96.7
5 4.08 2.45–7.46
Total 50 36 86 58.1 - -
1‘‘F’’ailure=(LPF, LCF, ETF); ‘‘S’’uccess=(ACPR).
2Percent failure (no. failures/row total).
3Relative risk of failure associated with mutant AA (relative to wild AA as reference) [RR=failure probability (mutant)/failure probability (wild)].
4Confidence interval (for RR).
5The presence of 164L of PfDHFR and 540E PfDHPS.
doi:10.1371/journal.pone.0006762.t002
SP Treatment Trial
PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6762collected on the day of failure from 12 patients classified as ETF
(PCT=2–3 days) to determine drug levels of both SDX and PYR
[29]. A median of 110619 mg/ml (high of 157 mg/ml) for SDX
and a median of 0.3160.13 mg/ml (high of 0.6 mg/ml) for PYR
were determined (data not shown).
In vitro drug susceptibility results
Forty six isolates collected from Padre Cocha prior to treatment
were adapted to in vitro culture and available for in vitro drug
susceptibility testing. Twenty of the isolates were from patients
classified as having ACPR (44%), 14 were from the LPF group
(30%), 11 (24%) were from the ETF group and 1 was from the
LCF group (2%). Figure 2 shows the IC50 values of SDX and PYR
according to clinical outcome [24] (Figure 2A) and number of
mutations (Figure 2B). In persons with ACPR, the geometric mean
IC50 value for SDX was 62 nM (95% CI: 28–139 nM) and 29 nM
(95% CI: 18–47 nM) for PYR. For persons who were treatment
failures the geometric mean IC50 values were 1892 nM (LPF),
5701 nM (LCF) and 5104 nM (ETF) for SDX and 145 nM (LPF),
156 nM (LCF) and 231 nM (ETF) for PYR (Figure 2A).
Therapeutic interactions between SDX and PYR were
investigated by estimating FIC values from IC50 measurements
taken in the presence of both drugs. When FIC values and clinical
outcomes were compared (Figure 3A), all isolates classified as
ACPR with IC50 values for SDX less than 85 nM (15/20; 80%)
and one isolate from a patient classified as LPF had FIC values
indicative of synergy (,0.6). The remaining parasites from the
LPF, LCF, ETF groups and those classified as having ACPR with
IC50 values greater than 85 nM had FIC values indicative of an
additive effect between SDX and PYR (0.6–1.5). When FIC values
were grouped based on the number of polymorphism (single,
sextuplet and septuplet), the majority of the parasites with a single
mutation showed synergy between the drug combination while
nearly all those containing the sextuplet and septuplet haplotypes
showed addition (Figure 3B).
Discussion
Developing a cost effective malaria drug resistance surveillance
program that can provide real time information and accurately
predict the rate of treatment success is pivotal in the fight against
this disease. Monitoring drug resistance worldwide is accomplished
by in vivo drug efficacy trials, monitoring in vitro drug susceptibility
values and detecting molecular markers. The easiest and most cost
effective means of surveillance is monitoring the progression of
polymorphisms associated with resistance, but the number of
molecular markers currently known to confer resistance is limited.
Figure 1. Flow chart of the enrollment process for the SP in vivo efficacy trial.
doi:10.1371/journal.pone.0006762.g001
SP Treatment Trial
PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6762In vivo efficacy trials are the gold standard for determining drug
resistance in real-time but these trials are costly and are not usually
feasible for routine surveillance. In vitro drug susceptibility testing
has been used extensively to determine sensitivity values but
culturing of ex vivo parasites can be costly and difficult. We report a
combination of all methods, including use of drug levels, and
correlate the effects of polymorphism on in vitro IC50 values and in
vivo efficacy.
In Peru, the presence of the septuplet haplotype (BR/51I/
108N/164L and 437G/540E/581G) was a near absolute
predictor of treatment failure. A limitation of the current study
was the presence of only three two-locus haplotypes, making it
impossible to discern the effects other haplotype combinations had
on clinical outcomes in this region. In lieu of genotyping the entire
DHFR and DHPS, we report that the presence of mutations at
164L of DHFR and 540E of PfDHPS were excellent predictors of
treatment failures. While the presence of the 164L mutation in
Peruvian isolates is associated with high levels of SP resistance, it
remains rare in Africa, despite being common in Asia and South
America [15]. Interestingly, the presence of BR sequence was
always associated with the 164L polymorphism. While the Bolivia
repeat has been reported to be benign, the reason for such an
insertion is unknown and currently has not been reported in
Africa. On-going molecular studies using clinical isolates of P.
falciparum collected in 2006 and 2007 from the Amazon basin
region of Peru still show a strong association between the presence
of the BR and the 164L polymorphism. However, unlike the study
conducted in 1999, only 16% of the isolates have the BR and the
164L mutation which could be due to the loss of the selective
pressure when SP was removed from the health clinics (Bacon et
al, data not shown). Studies from Africa have shown that the triple
mutant in DHFR (51I, 59R and 108N) is useful in predicting
treatment failures but the widespread presence of 108N and the
absence of 59R in Peru prevents the use of this haplotype
combination for this means [30,31,32]. At the time this study was
conducted, we did not identify isolates of P. falciparum with the 50R
mutation but its presence has since been documented in other
South American countries [5].
We found that not all patients harboring isolates with multiple
mutations failed therapy, which could be due to the presence of
some degree of acquired immunity as shown in a patient
populations living in highly endemic regions [14,33]. As an
example, we documented that 7/36 (19%) patients that were
successfully treated with SP, harbored isolates with six or greater
mutations. Six of the seven subjects had reported at least one case
of malaria in the past 12 months, with 4/6 reporting a case of P.
falciparum and 2/6 reporting cases of P. vivax malaria. Two of the
four reporting previous P. falciparum cases, reported receiving
treatment with SP as first line therapy.
It has been shown that P. falciparum isolates collected in South
America [5,10], contain different haplotypes for the DHFR/
DHPS loci as compared to isolates circulating in Africa [31,34,35]
signifying a divergence of the 51I, 108N and 164L (South
America) and 51I, 59R and 108N (African) haplotypes. Microsat-
Figure 2. In vitro response (IC50s) of cultured adapted P. falciparum to sulfadoxine (SDX) and pyrimethamine (PYR) in relation to
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from South America with mutations conferring mid- and high-
level resistance to SP have a common origin [5] while African
isolates are similar to those present in Southeast Asia [36].
Additional studies on the evaluation of the genetic variability
around the highly resistant alleles in isolates from Africa provide
evidence of a selective sweep attributed to selection of widespread
use of pyrimethamine-sulfadoxine [37]. The presence of a limited
number of haplotypes (single, sextuplet and septuplet) in Peru
could be due to clonal expansion of a drug resistant parasite
imported to the region from Brazil. With just a few haplotypes,
selection of drug resistant phenotypes could have occurred, quickly
resulting in a rapid progression of drug treatment failures and
rapid removal of SP from the health centers. The ubiquitous
mutation at 108N seen in this study is fixed as it is seen in all areas
of Peru [38], regardless of treatment outcomes [10]. This mutation
has been detected in several malaria endemic regions across
Northern Peru, even in areas that still use SP as part of the
national treatment policy for uncomplicated malaria [38]. While
the 108N mutation appears to have no role in conferring
resistance in Peru, it could permit for the persistence of
gametocytes. In this study, 18 of the 19 patients with parasites
harboring the single mutation and classified as ACPR, had
gametocytes present 21–28 post treatment and mean AUC greater
than 3.0. This finding possibly signifies that this mutation, while
not singularly involved in conferring drug resistance, facilitates
persistence that allows for a greater likelihood of transmission of
genetically variant gametocytes to mosquitoes [13,25]. Since
resistance to SP occurs in a step-wise fashion with 108N being
the first mutation in the series, transmission of gametocytes with
this genotype could propagate further selection of a resistant
genotype and phenotype [39]. This is an important issue,
especially in regions where this combinational therapy is still
being used. While we did not perform transmission studies, others
have shown successful infectivity of mosquitoes with gametocytes
with resistant genotypes that emerged following treatment with
chloroquine [40] and SP [13].
Many published reports have described the effects of mutations
in PfDHFR and PfDHPS on clinical success and failure following
treatment with SP. However, very little is known if the effects of
point mutations on in vitro drug susceptibility levels where the
clinical outcomes are also known [16]. When using the threshold
values published previously as IC50 values at or above 100 nM
considered to be resistant [41,42], we found that isolates with a
single mutation at 108N in DHFR (22 isolates) had an IC50
geometric mean for PYR of 33 nM, which is lower than that
reported previously [41]. Defining this subset of parasites with
regards to the two-locus haplotype as having in vitro sensitive levels
for PYR even though they have the 108N mutation, provides
insight into the significance of this mutation and its usefulness at
predicting in vivo efficacy in this region of the Amazon. The
relationship between in vitro and in vivo resistance to SDX/PYR
showed that resistance to SDX is directly related in most cases to
treatment failure. This data is supported by the in vitro drug
Figure 3. The derived isobolograms for the interaction of SDX and PYR and how they related to treatment outcome (Panel A: ACPR N,
LPFD, LCF %, ETF,) and genotypes (Panel B: single N, sextuplet D, septuplet%). FIC,0.59(dashed line) was classified as synergy; 0.6–1.5 was
classified as additive (solid line) and .1.5 was classified as antagonism.
doi:10.1371/journal.pone.0006762.g003
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PYR was synergistic in most of the parasites that were sensitive to
therapy, whereas the drug combination was additive in all of the
ETF/LPF/LCF outcomes (Figures 1 and 2). To fully understand
drug resistance, determining the pharmacokinetics of various drug
combination is essential [21]. With regards to SP, sulphadoxine is
absorbed relatively slowly with a reported maximum concentra-
tion calculated to be up to 170 ug/ml (median 63.9 mg/ml) in a
model median time of 24 h while pyrimethamine is absorbed
quickly, reaching a reported maximum concentration of up to
1279 ng/ml (median 281 ng/ml) in a median time of 9.3 h [21].
The median values for both drugs are similar to those previously
reported following administration of a standard dose of SP [29]. In
this study, we report that 12 patients classified as ETF had median
whole blood concentration from serum samples collected on day of
failure (PCT=2–3 days) for SDX and PYR of 110 mg/ml and
310 ng/ml, respectively. These values are similar to median values
of 63.9 mg/ml and 281 ng/ml for SDX and PYR, respectively,
previously published [21]. Given the half life of 6.7 days for SDX
and PYR of 3.2 days [21], the serum levels obtained for this study
were still within the therapeutic range even after 2–3 post
treatment, which strongly suggests that failures were due to the
presence of multiple mutation in DHFR and DHPS.
While complete publication of these results are occurring several
years after the study was completed, the results of the in vivo
efficacy trial were used by the Peruvian Ministry of Health, to
support change in the national treatment policy for malaria [43].
What is relevant to on-going studies worldwide are the threshold of
resistance for in vitro IC50 values and how they correlate with the
various two-locus haplotypes. A bench mark can now be set to
assist on-going surveillance for drug resistance against this
combinational therapy in this region of the Amazon basin of
South American. Continued surveillance in the absence of
selective drug pressure, may reveal that SP may be suitable for
future use in combination therapy in this region.
Materials and Methods
Study sites
A single in vivo therapeutic efficacy trial was conducted at two
different sites located in low transmission regions of the Peruvian
Amazon region in March-August 1999 when SP was recommend-
ed by the Peruvian National Malaria Control Program as first line
treatment for uncomplicated malaria. One study site was located
in the town of Padre Cocha, a village of 1400 inhabitants located
on the Nanay River approximately five kilometers northwest of
Iquitos, the capital of Loreto, Peru. A second study site was located
in the town of Caballococha, which is approximately 300 km west
of Padre Cocha, with a population of 3,300 and is located in the
northeastern Peruvian Amazon region on the Peruvian border
with Colombia and Brazil. The study was conducted following a
protocol approved by the Walter Reed Army Institute of Research
Human Use and Review Committee (Protocol No. 719) and by
the Universidad Peruana Cayetano Heredia Ethics Committee
report # CAR-017-DUIICT-99, under Protocol # 719. The
protocol for this trial and supporting CONSORT checklist are
available as supporting information; see checklist S1 and protocol
S1.
Patient enrollment
The procedure used for the in vivo drug efficacy study followed
recommendations of the World Health Organization [24,44].
Patients $6 month of age with suspected malaria were screened
for malaria parasitemia with thick blood smears. There was no
upper age limit designated for this study. Blood smears were
stained with Giemsa and the parasite densities calculated by
dividing the number of asexual parasites per 200 white blood cells
and multiplying by the actual number of WBCs as determined by
the QBC centrifugal hematology system (Becton Dickinson,
Franklin Lakes, NJ). Patients presenting with P. falciparum asexual
monoinfections, a parasite density greater than 500 parasites/mL
but less than 200 parasites per oil immersion field (Ministry of
Health, quantification of 4+), oral temperature $38.5uC (101uF)
and/or a history of fever in the last 72 hours, and available and
willing to return for follow-up were consented and enrolled in the
trial using an IRB approved written consent form. In a subset of
enrolled patients, gametocyte densities were determined on days 0,
2, 3, 4, 7, 14, 21 and 28 by counting sexual parasites per 200
WBCs. Patients that exhibited signs of severe malaria such as not
being able to drink or breast feed, repeated vomiting, convulsions,
lethargic or unconscious state, unable to sit or stand up.
Respiratory distress or jaundice were not enrolled or followed
clinically in this study but were referred to the local clinical care
provides for hospitalization and treatment. Children under the age
of 6 months were referred to the health clinic for diagnosis and
treatment.
Sulfadoxine-pyrimethamine (Fansidar
H; Roche S.A., Basel,
Switzerland) was administered in a single oral dose equivalent to
1.25 mg/kg of pyrimethamine (up to a max of 75 mg) on Day 0
and were then followed with clinical histories, physical examina-
tions, oral temperature measurements, and thick blood smears on
days 1, 2, 3, 4, 7, 14, 21 and 28 to verify response. Patients that
failed treatment with SP were treated on day of failure with a
combination of quinine and tetracycline, quinine and chloroquine
or quinine, tetracycline and primaquine.
Treatment efficacy evaluation
Treatment outcomes were assessed using both the WHO
standard definition for clinical [24] and parasitological responses
[23]. To distinguish between recrudescence and reinfection,
malaria parasites collected on day of enrollment (day 0) and day
of recurrence were genotyped by RFLP analysis of a 700 bp PCR
product of Pfmsp2 [26] and DNA sequencing a 400 bp PCR
product from Pfmsp1 block 2 [27]. We previously reported that
Pfmsp1 block 2 is highly variable in this region of the Amazon
basin, with at least eight different allelic variants circulating in the
P. falciparum population, making it a suitable candidate for
genotyping experimentation when used in conjunction with Pfmsp2
[27].
In vitro culturing of isolates
Fresh clinical Plasmodium falciparum isolates were cultured on
average 8–12 weeks in vitro by a modification of the method of
Trager and Jensen [45]. Parasitemia levels were determined by
counting Giemsa-stain thin blood films. Parasites were initially
adapted to culture in standard RPMI-1640. P. falciparum clones
that are SP resistant (CDC/Indochina III (W-2), and sensitive
CDC/Sierra Leone I (D6), [46] were used as reference standards.
In vitro antimalarial drug susceptibility testing
The drug susceptibility test was based on the method described
by Desjardins, et al., [47] with modifications developed by
Milhous, et al. [48]. The antimalarials used in the study were
obtained from the Division of Experimental Therapeutics, Walter
Reed Army Institute of Research, Silver Spring, MD. Sulfadoxine
and pyrimethamine were tested singly and in combination with six
of the field isolates at fixed ratios of 1:1, 1:3, 3:1, 1:4, 4:1, and 1:5.
The 50% inhibitory concentrations (IC50’s) were determined for
SP Treatment Trial
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regression software–NFIT (University of Texas, Medical Branch,
Galveston). IC50 values at or above 100 nM were considered
indicative of resistance for both pyrimethamine and sulfadoxine
[41,42]. The IC50’s were used to calculate 50% fractional
inhibitory concentrations (FIC50’s) singly and in combination as
described by Berenbaum et al.[49]. The FIC50’s were expressed
with the following equation FIC Drug A=IC50A(B)/IC50A, where
IC50A (B) is the 50% inhibitory concentration of drug A in the
presence of drug B. The sum of FICs (gFICs) of drug A and B at
1:1 concentration ratio were used to determine the interaction of
S/P in vitro. Isobolograms from a limited number of isolates
defined the drug-drug interaction as follows: interactions were
classified as synergism with sum FICs (SFICs) #0.6, as additive
with SFICs 0.61–1.5 and antagonistic with SFICs .1.5 [50].
Molecular markers determination to identify Pfdhfr/
Pfdhps SNPs
Parasite DNA was extracted from 200 mL of whole blood
collected on the day of enrollment from a three ml Vacutainer
(Becton Dickson) with EDTA using QIAampH DNA blood mini
kit (Qiagen, Valencia, Ca) according to manufacturer’s instruc-
tions. Five mlo fP. falciparum genomic DNA was used for a PCR
reaction using Pfdhfr and Pfdhps specific primers [32,51]. PCR
products were DNA sequenced to detect mutations A16V,
S108T/N, C50R, N51I, C59R, I164L and the Bolivia repeat in
Pfdhfr and S436A and A437G, K540E, A581G and A613T/S in
Pfdhps [32,51,52].
Statistical analysis
Statistical analyses were carried out using Minitab (Vs 14) and
StatXact (Vs 4.01). Mean or geometric mean values were used to
summarize quantitative measurements (age, weight, hemoglobin
(Hb), drug IC50 values, parasite counts). Due to frequent travel for
work, and the uncertainty where the cases of malaria were
contracted, treatment outcomes from each site were combined.
Unpaired t-tests (or one way ANOVA) were used to compare
mean values in two (or . two) independent groups. Drug IC50
values and parasite counts were log transformed (base10) before
analysis. Fisher’s exact test was used to compare two independent
proportions. McNemar’s was be used to compare two dependent
(paired) proportions. Multivariate logistic regression was used to
help assess statistically significant predictors of treatment success/
failure For single categorical predictor variables the relative risk
(RR) for treatment failure and corresponding 95% confidence
intervals (CIs) were computed. In all cases the reference group for
assessing increased risk of failure is the category with the assumed
lowest risk of treatment failure. For example, in assessing risk in
relation to the total number of possible haplotypes in Pfdhfr/dhps
(single, sextuplet and septuplet), the reference group is the category
with a ‘‘single mutation’’. Because of the close agreement between
the two WHO systems for assessing therapeutic outcomes only the
results using the clinical outcomes as defined in the WHO 2003
system are reported. All reported p-values are two-sided and 95%
CIs were computed for important comparisons (effect measures).
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